Questions? Call 888-624-8373

PAPERBACK
list:$43.00
Web:$38.70
add to cart

Rights & Permissions

Free PDF Access
topleft topright

Immunization Safety Review: Influenza Vaccines and Neurological Complications (2004)
Board on Health Promotion and Disease Prevention (HPDP)
 Institute of Medicine (IOM)

Page
147
bottomleft bottomright
  E-mail
 Facebook
 Digg
 Stumble
 Twitter
More
Page
147

Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 147
INFLUENZA VACCINES AND NEUROLOGICAL COMPLICATIONS REFERENCES 147 Albert LJ, Inman RD. 1999. Molecular mimicry and autoimmunity. NEngl JMed 341(27):2068-74. Alter M, Leibowitz U. Speer J. 1966. Risk of multiple sclerosis related to age at immigration to Israel. Arch Neurol 15(3):234-7. Asbury AK. 2000. New concepts of Guillain-Barre syndrome. J Child Neurol 15(3):183-91. ATSDR (Agency for Toxic Substances and Disease Registry). 1999. Toxicological Profile for Mercury (Update). Bach IF, Chatenoud L. 2001. Tolerance to islet autoantigens in type 1 diabetes. Annu Rev Immunol 19:131-61. Bakshi R. Mazziotta JC. 1996. Acute transverse myelitis after influenza vaccination: magnetic reso- nance imaging findings. J. Neuroimaging 6(4):248-50. Bamford CR, Sibley WA, Laguna IF. 1978. Swine influenza vaccination in patients with multiple sclerosis. Arch Neurol 35(4):242-3. Belshe RB, Couch RB, Glezen WP, Treanor IT. 2002. Live attenuated intranasal influenza vaccine. Vaccine 20(29-30):3429-30. Benoist C, Mathis D. 2001. Autoimmunity provoked by infection: how good is the case for T cell epitope mimicry? Nat Immunol 2(9):797-801. Berna Biotech Ltd. 2002. News Release: Berna Biotech to accelerate development of a 2nd genera- tion nasal flu vaccine product. [online] Available at: http://www.bernabiotech.com/news/ archive/article/20020606_01.html [accessed June 6, 2002]. Beyer WE, Palache AM, Osterhaus ADME. 1998. Comparison of serology and reactogenicity between influenza subunit vaccines and whole virus or split vaccines: a review and meta- analysis of the literature. Clin Drug Invest; 15(1):1-12. Beyer WE, Palache AM, de Jong JC, Osterhaus AD. 2002. Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis. Vaccine 20(9-10):1340-53. Bostrom A. 1997. Vaccine risk communication: Lessons from risk perception, decision making and environmental risk communication research. Risk. [online] Available at: http://www.piercelaw. edu/risk/vol8/spring/bostrom.htm. Breman JG, Hayner NS. 1984. Guillain-Barre syndrome and its relationship to swine influenza vaccination in Michigan, 1976-1977. Am JEpidemiol 119(6):880-9. Bridges C, Thompson W. Meltzer M, Reeve G. Talamonti W. Cox N. Lilac H. Hall H. Klimov A, Fukuda K. 2000. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial. JAMA 284(13):1655-63. Brooks R. Reznik A. 1980. Guillain-Barre syndrome following trivalent influenza vaccine in an elderly patient. Mt Sinai J Med 47(2): 190-1. Brostoff SW, White TM. 1982. Absence of P2 protein in swine flu vaccines. JAMA 247(4):495. Burwen D. 2003 (March 13). Use of Medicare Data to Evaluate Adverse Events After Influenza Vaccine. Presentation to the Institute of Medicine Meeting on Influenza Vaccine and Neuro- logical Complications, Washington, DC. Institute of Medicine. Immunization Safety Review Committee. Buzby JC, Allos BM, Roberts T. 1997. The economic burden of Campylobacter-associated Guillain- Barre syndrome. JInfectDis 176 Suppl 2:S192-7. CDC.l999. Primary and Secondary Syphilis United States, 1998. MMWR 48(30):885-90. CDC. 2002a. Epidemiology and Prevention of Vaccine-Preventable Diseases 7th Edition. Public Health Foundation. CDC. 2002b. Prevention and Control of Influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP); MMWR Morb Mortal Wkly Rep 51(RR03):1-31. CDC. 2002c. Surveillance for Influenza United States, 1997-98, 1998-99, and 1999-00 Seasons. MMWR Morb Mortal Wkly Rep 51(SS-7):1-10.

OCR for page 148
148 IMMUNIZATION SAFETY REVIEW CDC. 2003a. Infant Botulism New York City, 2001-2002. MMVER Morb Mortal Wkly Rep 52 (2):26-28. CDC. 2003b. Influenza and Pneumococcal Immunization: a Qualitative Assessment of the Beliefs of Physicians and Older Hispanic and African Americans. [online] Available at: http:// www.cdc.gov/nip/flu/flu_qualresearch.htm. [accessed September 9, 2003]. CDC. 2003c. National Center for Infectious Diseases. Influenza: The Disease. [online] Available at: www.cdc.gov/ncidod/diseases/flu/fluinfo.htm [accessed March 20, 2003]. CDC. 2003d. Prevention and control of influenza: Recomendations of the Advisory Committee on Immunization Practices (ACIP). MMVER Morb Mortal Wkly Rep 52 (RR08): 1-36. CDC. 2003e. Personal Communication with P. Haber. VAERS reports. March, 2003. Cha TA, Kao K, Zhao J. Fast PE, Mendelman PM, Arvin A. 2000. Genotypic stability of cold- adapted influenza virus vaccine in an efficacy clinical trial. J Clin Microbiol 38(2):839-45. Chen R. 2003 (March 13). Studies Of Guillain-Barre Syndrome (GBS) After Influenza Vaccination. Presentation to the Immunization Safety Review Committee, Washington, DC. Confavreux C, Suissa S. Saddler P. Bourdes V, Vukusic S. for the Vaccines in Multiple Sclerosis Study Group. 2001. Vaccinations and the risk of relapse in multiple sclerosis. N Engl J Med 344(5):319-326. Davidson A, Diamond B. 2001. Autoimmune diseases. N Engl J Med 345(5):340-50. De Keyser J. Zwanikken C, Boon M. 1998. Effects of influenza vaccination and influenza illness on exacerbations in multiple sclerosis. JNeurol Sci 159(1):51-3. Department of Health and Human Services (DHHS). 2003. Product Approval Information. [online] Available at: www.fda.gov/cber/approvltr/inflmedO61703L.htm [accessed July 16, 2003]. DeStefano F. Verstraeten T. Jackson LA, Okoro C, Benson P. Black S. Shinefield H. Mullooly P. Likosky W. Chen R. 2003. Vaccinations and risk of central nervous system demyelinating diseases in adults. Arch Neurol 60:504-9. Dolin R. 2001. Influenza. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, eds. Harrison's Principles of Internal Medicine. 15th ed. New York: McGraw-Hill. Pp. 1125-30. Dowdle WR. 1997. Pandemic influenza: confronting a re-emergent threat. The 1976 experience. J Infect Dis 176 Suppl 1 :S69-72. Ellenberg S. Chen R. 1997. The complicated task of monitoring vaccine safety. Public Health Reports 112:10-20. EPA (Environmental Protection Agency). 1997. Mercury Study Report to Congress: Volume 1 Ex- ecutive Summary. EPA 452/R-97-003. Evans DM, Dunn G. Minor PD, Schild GC, Cann AJ, Stanway G. Almond JW, Currey K, Maizel JV. 1985. Nature 11-17;314(6011):548-50 Fischoff B. Slovic P. Lichtenstein S. Read S. Combs B. 2000. How safe is safe enough? A psycho- metric study of attitudes toward technological risks and benefits. In: Slovic P. ed. The Percep- tion of Risk. London: Earthscan Publications. France E. 2003 (March 13). Safety of the Trivalent Inactivated Influenza Vaccine (TIV) Among Children: A Population-Based Study. Presentation to the Immunization Safety Review Com- mittee. Washington, DC. Fu TM, Guan L, Friedman A, Schofield TL, Ulmer JB, Liu MA, Donnelly JJ. 1999. Dose depen- dence of CTL precursor frequency induced by a DNA vaccine and correlation with protective immunity against influenza virus challenge. J Immunol 162(7):4163-70. Geier M, Geier D, Zahalsky A. 2003. Influenza vaccination and Guillain-Barre syndrome. Clin Immun 107 (2003):116-21. Gonzalez M, Pirez MC, Ward E, Dibarboure H. Garcia A, Picolet H. 2000. Safety and immuno- genicity of a paediatric presentation of an influenza vaccine. Arch Dis Child 83(6):488-91. Griffin J. 2003 (March 13). Guillain-Barre' Syndrome. Presentation to the Immunization Safety Review Committee. Washington, DC..

OCR for page 149
INFLUENZA VACCINES AND NEUROLOGICAL COMPLICATIONS 149 Haber P. 2003 (March 13). Influenza Vaccine and Neurological Adverse Events. VAERS 7/1990 - 1/ 2003. Presentation to the Immunization Safety Review Committee. Washington, DC. Hahn AF. 1996. Experimental allergic neuritis (EAN) as a model for the immune-mediated demyeli- nating neuropathies. Rev Neurol (Paris) 152(5):328-32. Halperin SA, Smith B. Mabrouk T. Germain M, Trepanier P. Hassell T. Treanor J. Gauthier R. Mills EL. 2002. Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture- derived influenza vaccine in healthy adults, seniors, and children. Vaccine 20(7-8):1240-7. Hamada T. Driscoll BE, Kies MW, Alvord EC Jr. 1989. LPS augments adoptive transfer of experi- mental allergic encephalomyelitis in the Lewis rat. Autoimmunity 2(4):275-84. Hilleman MR. 2002. Realities and enigmas of human viral influenza: pathogenesis, epidemiology and control. Vaccine 20(25-26):3068-87. Hjorth RN, Bonde GM, Finer E, Hartzell RW, Rorke LB, Rubin BA. 1984. Experimental neuritis induced by a mixture of neural antigens and influenza vaccines. A possible model for Guillain- Barre syndrome. JNeuroimmunol 6(1):1-8. Hochberg F. Nelson K, Janzen W. 1975. Influenza type B-related encephalopathy. The 1971 out- break of Reye syndrome in Chicago. JAMA 231(8):817-21. Houff SA, Miller GL, Lovell CR, Wallen WC, Madden DL, Sever JL, Dolin R. 1977. The Guillain- Barre syndrome and swine influenza vaccination. Trans Am Neurol Assoc 102: 120-3. Hughes RA, Rees JH. 1997. Clinical and epidemiologic features of Guillain-Barre syndrome. JInfect Dis 176 Suppl 2:S92-8. Hughes RA, Raphael JC, Swan AV, van Doorn PA. 2001. Intravenous immunoglobulin for Guillain- Barre syndrome. Cochrane Database Syst Rev (2):CD002063. Hurwitz ES, Schonberger LB, Nelson DB, Holman RC. 1981. Guillain-Barre syndrome and the 1978-1979 influenza vaccine. NEngl JMed 304(26):1557-61. IOM (Institute of Medicine). 1991. Adverse Events Following Pertussis and Rubella Vaccines. Washington DC: National Academy Press. IOM (Institute of Medicine).1994a. Adverse Events Associated with Childhood Vaccines: Evidence Bearing on Causality. Washington DC: National Academy Press. IOM (Institute of Medicine). 1994b. DPT Vaccine and Chronic Nervous System Dysfunction: A New Analysis. Washington DC: National Academy Press. IOM (Institute of Medicine). 2001a. Immunization Safety Review: Measles-Mumps-Rubella Vaccine and Autism. Washington, DC: National Academy Press. IOM (Institute of Medicine). 2001b. Immunization Safety Review: Thimerosal-Containing Vaccines and Neurodevelopmental Disorders. Washington DC: National Academy Press. IOM (Institute of Medicine). 2001c. Multiple Sclerosis: Current Status and Strategies for the Future. Washington DC: National Academy Press. IOM (Institute of Medicine). 2002a. Immunization Safety Review: Hepatitis B Vaccine and Demyeli- nating Neurological Disorders. Washington DC: National Academy Press. IOM (Institute of Medicine). 2002b. Immunization Safety Review: Multiple Immunizations and Immune Dysfunction. Washington DC: National Academy Press. IOM (Institute of Medicine). 2002c. Immunization Safety Review: SV40 Contamination of Polio Vaccine and Cancer. Washington, DC: The National Academies Press. IOM (Institute of Medicine). 2003. Immunization Safety Review: Sudden Uxexpected Death in Infancy. Washington, DC: The National Academies Press. Jacobs BC, Rothbarth PH, van der Meche FG, Herbrink P. Schmitz PI, de Klerk MA, van Doorn PA. 1998. The spectrum of antecedent infections in Guillain-Barre syndrome: a case-control study. Neurology 51(4): 1110-5. Jahnke U. Fischer EH, Alvord EC Jr. 1985. Sequence homology between certain viral proteins and proteins related to encephalomyelitis and neuritis. Science 229(4710):282-4. Johnson DE. 1982. Guillain-Barre syndrome in the U.S. Army. Arch Neurol 39(1):21-4. Joseph SA, Tsao CY. 2002. Guillain-Barre syndrome. Adolesc Med 13(3):487-94.

OCR for page 150
150 IMMUNIZATION SAFETY REVIEW Kaplan JE, Katona P. Hurwitz ES, Schonberger LB. 1982. Guillain-Barre syndrome in the United States, 1979-1980 and 1980-1981. Lack of an association with influenza vaccination. JAMA 248(6):698-700. Kawasaki A, Purvin VA, Tang R. 1998. Bilateral anterior ischemic optic neuropathy following influenza vaccination. J. Neuroophthalmol 18(1):56-9. Keegan BM, Noseworthy JH. 2002. Multiple sclerosis. Annu Rev Med 53:285-302. Keenlyside RA, Schonberger LB, Bregman DJ, Bolyai JZ. 1980. Fatal Guillain-Barre syndrome after the national influenza immunization program. Neurology 30(9):929-33. Kilbourne ED, Arden NH. 1999. Inactivated Influenza. In: Plotkin SA, Orenstein W. eds. Vaccines. 3rd ed. Philadelphia: W.B. Saunders Company. Pp. 531-51. Kinnunen E, Junttila O. Haukka J. Hovi T. 1998. Nationwide oral poliovirus vaccination campaign and the incidence of Guillain-Barre syndrome. Am J Epidemiol 147(1):69-73. Kitch EW, Evans G. Gobin R. 1999. U.S. law. In: Plotkin SA, Orenstein W. eds. Vaccines. 3rd ed. Philadelphia: W.B. Saunders Company.Pp. 1165-67. Knight RS, Duncan JS, Davis CJ, Warlow CP. 1984. Influenza vaccination and Guillain-Barre syn- drome. Lancet 1(8373):394. Kurland LT, Molgaard CA, Kurland EM, Wiederholt WC, Kirkpatrick JW. 1984. Swine flu vaccine and multiple sclerosis. JAMA 251(20):2672-5. Kurland LT, Wiederholt WC, Beghe E, Kirkpatrick JW, Potter HG, Armstrong FP. 1986. Guillain- Barre syndrome following (a/New Jersey/76) influenza (swine flu) vaccine: epidemic or arti- fact? In Poeck K, Freund HJ, Ganshirt H. eds. Neurology: Proceedings of the XIIIth World Congress of Neurology, Hamburg, September 1-6, 1985. Berlin; New York: Springer-Verlag. Kurtzke JF, Beebe GW, Nagler B. Nefzger MD, Auth TL, Kurland LT. 1970. Studies on the natural history of multiple sclerosis. V. Long-term survival in young men. Arch Neurol 22(3):215-25. Langmuir AD. 1979. Guillain-Barre syndrome: the swine influenza virus vaccine incident in the United States of America, 1976-77: preliminary communication. J R Soc Med 72(9):660-9. Langmuir AD, Bregman DJ, Kurland LT, Nathanson N. Victor M. 1984. An epidemiologic and clinical evaluation of Guillain-Barre syndrome reported in association with the administration of swine influenza vaccines. Am J Epidemiol 119(6):841-79. Lamer AJ, Farmer SF. 2000. Myelopathy following influenza vaccination in inflammatory CNS disorder treated with chronic immunosuppression. Eur J Neurol 7(6):731-3. Lasky T. 2003 (March 13). Influenza Vaccine and GBS. Presentation to the Immunization Safety Review Commitee. Washington, DC. Lasky T. Terracciano GJ, Magder L, Koski CL, Ballesteros M, Nash D, Clark S. Haber P. Stolley PD, Schonberger LB, Chen RT. 1998. The Guillain-Barre syndrome and the 1992-1993 and 1993-1994 influenza vaccines. NEngl J Med 339(25):1797-802. Leask JA, Chapman S. 1998. An attempt to swindle nature: press anti-immunization reportage 1993- 1997. Aust N Z J Public Health 22(1): 17-26. Ledeen R. 1985. Gangliosides of the neuron. Trends Neurosci 8(4): 169-174. Levandowski R. 2003 (March 13). Influenza Vaccine Production. Presentation to the Immunization Safety Review Committee. Washington, DC. Lin YP, Shaw M, Gregory V, Cameron K, Lim W. Klimov A, Subbarao K, Guan Y. Krauss S. Shortridge K, Webster R. Cox N. Hay A. 2000. Avian-to-human transmission of H9N2 subtype influenza A viruses: relationship between H9N2 and H5N1 human isolates. Proc Natl Acad Sci USA 97(17):9654-8. Lublin FD, Reingold SC. 1996. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clini- cal Trials of New Agents in Multiple Sclerosis. Neurology 46(4):907-11. Maassab HF, Bryant ML. 1999. The development of live attenuated cold-adapted influenza virus vaccine for humans. Rev Med Virol 9(4):237-44.

OCR for page 151
INFLUENZA VACCINES AND NEUROLOGICAL COMPLICATIONS 151 Magira BE, Papaioakim M, Nachamkin I, Asbury AK, Li CY, Ho TW, Griffin JW, McKhann GM, Monos DS. 2003. Differential distribution of HLA-DQ beta/DA beta epitopes in the two forms of Guillain-Barre syndrome, acute motor axonal neuropathy and acute inflammatory demyeli- nating polyneuropathy (AIDP): identification of DQ beta epitopes associated with susceptibility to and protection from AIDP. J. Immunol 170(6):3074-80. Marks IS, Halpin TJ. 1980. Guillain-Barre syndrome in recipients of A/New Jersey influenza vac- cine. JAMA 243(24):2490-4. Marrack P. Kappler J. Kotzin BL. 2001. Autoimmune disease: why and where it occurs. Nat Med 7(8):899-905. Miller AK, Morgante LA, Buchwald LY, Nutile SM, Coyle PK, Krupp LB, Doscher CA, Lublin FD, Knobler RL, Trantas F. Kelley L, Smith CR, La Rocca N. Lopez S. 1997. A multicenter, randomized, double-blind, placebo-controlled trial of influenza immunization in multiple scle- rosis. Neurology 48(2):312-4. Mokhtarian F. Shirazian D, Morgante L, Miller A, Grob D, Lichstein E. 1997. Influenza virus vaccination of patients with multiple sclerosis. Mult Scler 3(4):243-7. Moran AP, Prendergast MM. 2001. Molecular mimicry in Campylobacter jejuni and Helicobacter pylori lipopolysaccharides: contribution of gastrointestinal infections to autoimmunity. J Autoimmun 16(3):241-56. Moran AP, Prendergast MM, Hogan EL. 2002. Sialosyl-galactose: a common denominator of Guillain-Barre and related disorders. J. Neurol Sci 196(1-2): 1-7. Morishima T. Togashi T. Yokota S. Okuno Y. Miyazaki C, Tashiro M, Okabe N. 2002. Encephalitis and encephalopathy associated with an influenza epidemic in Japan. Clin Infect Dis 35(5):512-7. Myers LW, Ellison GW, Lucia M, Novom S. Holevoet M, Madden D, Sever J. Noble GR. 1977. Swine influenza virus vaccination in patients with multiple sclerosis. J Infect Dis 136 Suppl:S546-54. Nachamkin I. 2002. Rabbit model of Guillain-Barre syndrome. Ann Neurol 52(1):127-8. National Institute of Neurological Disorders and Stroke (NINDS). 2001. Guillain-Barre Syndrome Information Page. [Online]. Available: http://www.ninds.nih.gov/health_and_medical/disorders/ gbs.htm [accessed March 20, 2003]. Neirynck S. Deroo T. Saelens X, Vanlandschoot P. Jou WM, Fiers W. 1999. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 5(10): 1157-63. Neuzil KM, Dupont WD, Wright PF, Edwards KM. 2001. Efficacy of inactivated and cold-adapted vaccines against influenza A infection, 1985 to 1990: the pediatric experience. Pediatr Infect Dis J 20(8):733-40. Newland JG, Romero JR, Varman M, Drake C, Holst A, Safranek T. Subbarao K. 2003. Encephalitis associated with influenza B virus infection in 2 children and a review of the literature. Clin Infect Dis 36(7):87-95. Nichol K. 2001. Cost-benefit analysis of a strategy to vaccinate healthy working adults against influenza. Arch Intern Med 161(5):749-59. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. 2000. Multiple sclerosis. N Engl J Med 343(13):938-52. NRC (National Research Council). 2000. Toxicological Effects of Methylmercury. Washington, D.C.: National Academy Press. Okuda K, Ihata A, Watabe S. Okada E, Yamakawa T. Hamajima K, Yang J. Ishii N. Nakazawa M, Okuda K, Ohnari K, Nakajima K, Xin KQ. 2001. Protective immunity against influenza A virus induced by immunization with DNA plasmid containing influenza M gene. Vaccine 19(27):3681-91. Osler LD, Sidell AD. 1960. The Guillain-Barre syndrome. N Engl J Med 262:964-969. Palese P. Garcia-Sastre A. 2002. Influenza vaccines: present and future. J Clin Invest 110(1):9-13. Parkin WE, Beecham HJ, Streiff E, Sharrar RG, Harris JC. 1978. Relationship studied in Penn- sylvania. Guillain-Barre syndrome and influenza immunization. Pa Med 81(4):47-8, 50-2.

OCR for page 152
52 IMMUNIZATION SAFETY REVIEW PDR. 2003. Physicians Desk Reference, 57th edition. Thomson PDR. Montvale, NJ. Pfleiderer M, Lower J. Kurth R. 2001. Cold-attenuated live influenza vaccines, a risk-benefit assess- ment. Vaccine 20(5-6):886-94. Piedra PA, Glezen WP, Mbawuike I, Gruber WC, Baxter ED, Boland FJ, Byrd RW, Fan LL, Lewis JK, Rhodes LJ, Whitney SE, Taber LH. 1993. Studies on reactogenicity and immunogenicity of attenuated bivalent cold recombinant influenza type A (CRA) and inactivated trivalent influ- enza virus (TI) vaccines in infants and young children. Vaccine 11(7):718-24. Plotkin SA, Rupprecht CE, Koprowski H. 1995. Rabies vaccine. In: Plotkin SA, Orenstein W. eds. Vaccines. 3rd ed. Philadelphia: W.B. Saunders Company. Pp. 743-66. Poser CM, Behan PO. 1982. Late onset of Guillain-Barre syndrome. J Neuroimmunol 3(1):27-41. Poser CM, Roman G. Emery ES. 1978. Recurrent disseminated vasculomyelinopathy. Arch Neurol 35(3): 166-70. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW. 1983. New diagnostic criteria for multiple sclerosis: guide- lines for research protocols. Ann Neurol 13(3):227-31. Postic B. Delaney JF, Miller RA. 1980. Landry-Guillain-Barre syndrome following influenza A/New Jersey/76 vaccine: case report. Mil Med 145(8):561-2. Purvin V. 1998. Optic neuritis. Curr Opin Ophthalmol 9(6):3-9. Rantala H. Cherry JD, Shields WD, Uhari M. 1994. Epidemiology of Guillain-Barre syndrome in children: relationship of oral polio vaccine administration to occurrence. JPediatr 124(2):220-3. Raphael JC, Chevret S. Hughes RA, Annane D. 2001. Plasma exchange for Guillain-Barre syn- drome. Cochrane Database Syst Rev (2):CD001798. Ray CL, Dreizin IJ. 1996. Bilateral optic neuropathy associated with influenza vaccination. J Neuroophthalmol 16(3): 182-4. Regner M, Lambert PH. 2001. Autoimmunity through infection or immunization? Nat Immunol 2(3): 185-8. Retailliau HF, Curtis AC, Storr G. Caesar G. Eddins DL, Hattwick MA. 1980. mness after influenza vaccination reported through a nationwide surveillance system, 1976-1977. Am J Epidemiol 111(3):270-8. Roscelli JD, Bass JW, Pang L. 1991. Guillain-Barre syndrome and influenza vaccination in the U.S. Army, 1980-1988. Am J Epidemiol 133(9):952-5. Rose NR. 2001. Infection, mimics, and autoimmune disease. J Clin Invest 107(8):943-4. Safranek TJ, Lawrence DN, Kurland LT, Culver DH, Wiederholt WC, Hayner NS, Osterholm MT, O'Brien P. Hughes JM. 1991. Reassessment of the association between Guillain-Barre syn- drome and receipt of swine influenza vaccine in 1976-1977: results of a two-state study. Expert Neurology Group. Am J Epidemiol 133(9):940-51. Saito H. Endo M, Takase S. Itahara K. 1980. Acute disseminated encephalomyelitis after influenza vaccination. Arch Neurol 37(9):564-6. Salvetti M, Pisani A, Bastianello S. Millefiorini E, Buttinelli C, Pozzilli C. 1995. Clinical and MRI assessment of disease activity in patients with multiple sclerosis after influenza vaccination. J Neurol 242(3):143-6. Salvetti M, Pisani A, Bastianello S. Millefiorini E, Buttinelli C, Pozzilli C. 1997. Influenza immun zation in multiple sclerosis. Neurology 49(5):1474-5. Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, Keenlyside RA, Ziegler DW, Retailliau HF, Eddins DL, Bryan JA. 1979. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976-1977. Am JEpidemiol 110(2):105-23. Seyal M, Ziegler DK, Couch JR. 1978. Recurrent Guillain-Barre syndrome following influenza vaccine. Neurology 28(7):725-6. Shaw SY, Laursen RA, Lees MB. 1986. Analogous amino acid sequences in myelin proteolipid and viral proteins. FEBS Lett 207(2):266-70.

OCR for page 153
INFLUENZA VACCINES AND NEUROLOGICAL COMPLICATIONS 153 Sheikh KA, Ho TW, Nachamkin I, Li CY, Cornblath DR, Asbury AK, Griffin JW, McKhann GM. 1998. Molecular mimicry in Guillain-Barre syndrome. Ann N YAcad Sci 845:307-21. Sheremata W. Eylar EH, Szymanska I, Sazant A. 1981. Peripheral nerve myelin P2 protein in influ- enza vaccine. Trans Am Neurol Assoc 106:221-3. Sibley WA, Bamford CR, Laguna IF. 1976. Influenza vaccination in patients with multiple sclerosis. JAMA 236(17):1965-6. Simonsen L, Fukuda K, Schonberger LB, Cox NJ. 2000. The impact of influenza epidemics on hospitalizations. J. Infect Dis 181(3):831-7. Singh B. 2000. Stimulation of the developing immune system can prevent autoimmunity. J Autoimmun 14(1):15-22. Singleton JA, Lloyd JC, Mootrey GT, Salive ME, Chen RT. 1999. An overview of the vaccine adverse event reporting system (VAERS) as a surveillance system. Vaccine 17:2908-17. Steinhauer DA, Skehel JJ. 2002. Genetics of influenza viruses. Annu Rev Genet 36:305-32. Stuve O. Zamvil SS. 1999. Pathogenesis, diagnosis, and treatment of acute disseminated encephalo- myelitis. Curr Opin Neurol 12(4):395-401. Sugaya N. 2002. Influenza-associated encephalopathy in Japan. Semin Pediatr Infect Dis 13(2):79-84. Sunderrajan EV, Davenport J. 1985. The Guillain-Barre syndrome: pulmonary-neurologic correla- tions. Medicine 64(5):333-41. Sutter RW, Cochi SL, Melnick JL. 1999. Live attenuated poliovirus vaccines. In: Plotkin SA, Orenstein W. eds. Vaccines. 3rd ed. Philadelphia: W.B. Saunders Company. Pp. 364-408. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N. Anderson LJ, Fukuda K. 2003. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289(2): 179-86. Vriesendorp FJ. 1997. Insights into Campylobacter jejuni-induced Guillain-Barre syndrome from the Lewis rat model of experimental allergic neuritis. J Infect Dis 176 Suppl 2:S 164-8. Wareing MD, Tannock GA. 2001. Live attenuated vaccines against influenza; an historical review. Vaccine 19(25-26):3320-30. Waubant E, Stuve O. 2002. Suspected mechanisms involved in multiple sclerosis and putative role of hepatitis B vaccine in multiple sclerosis. Commissioned background paper for IOM Immuniza- tion Safety Review Committee. Webster RG. 1997. Predictions for future human influenza pandemics. JInfectDis 176 Suppl l:S14-9. Webster RG. 1999. 1918 Spanish influenza: the secrets remain elusive. Proc Natl Acad Sci U S A 96(4): 1164-6. Webster R. 2003 (March 13). Influenza. Presentation to the Immunization Safety Review Committee.Washington, DC. Institute of Medicine. Weise MJ, Carnegie PR. 1988. An approach to searching protein sequences for superfamily relation- ships or chance similarities relevant to the molecular mimicry hypothesis: application to the basic proteins of myelin. JNeurochem 51(4):1267-73. Winer JB. 2001. Guillain-Barre syndrome. Mol Pathol 54(6):381-5. Winer JB, Hughes RA, Bradley GW, Scadding JW. 1984. Guillain-Barre syndrome and influenza vaccine. Lancet 1(8387):1182. Wucherpfennig KW. 2001. Mechanisms for the induction of autoimmunity by infectious agents. J Clin Invest 108(8): 1097-104. Yahr MD, Lobo-Antunes J. 1972. Relapsing encephalomyelitis following the use of influenza vac- cine. Arch Neurol 27(2):182-3. Yoshikawa H. Yamazaki S. Watanabe T. Abe T. 2001. Study of influenza-associated encephalitis/ encephalopathy in children during the 1997 to 2001 influenza seasons. J Child Neurol 16(12):885-90. Ziegler DW, Gardner JJ, Warfield DT, Walls HH. 1983. Experimental allergic neuritis-like disease in rabbits after injection with influenza vaccines mixed with gangliosides and adjuvants. Infect Immun 42(2):824-30.

OCR for page 154
154 IMMUNIZATION SAFETY REVIEW Ziegler T. Cox NJ. 1999. Influenza viruses. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken, eds. Manual of Clinical Microbiology. 7th ed. Washington, DC: ASM Press. Zimmerman RK, Nowalk MP, Santibanez TA, Jewell IK, Raymond M. 2003a. Shortage of influenza vaccine in 2000-2001: did it change patient beliefs? Am J Prev Med 24(4):349-53. Zimmerman RK, Santibanez TA, Janosky JE, Fine MJ, Raymund M, Wilson SA, Bardella IJ, Medsger AR, Nowalk MP. 2003b. What affects influenza vaccination rates among older patients? An analysis from inner-city, suburban, rural, and Veterans Affairs practices. Am J Med 114(1):31-8. Zinkernagel RM. 2001. Maternal antibodies, childhood infections, and autoimmune diseases. N Engl JMed 345(18):1331-5.

Representative terms from entire chapter:

multiple sclerosis